Search - tctmd.com

Displaying 1 - 20 of 431

Sort: Relevancy | Date

Side Effects of Statins Might Be Overstated: CTT Collaboration

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

February 06, 2026

Weight Loss Drugs Show Promise for Secondary Prevention in PAD

News Daily News

Weight Loss Drugs Show Promise for Secondary Prevention in PAD

February 04, 2026

JACC Debuts Data Digest on CV Health in the United States

News Daily News

JACC Debuts Data Digest on CV Health in the United States

January 12, 2026

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

AHA Highlights Single-Pill Combo Therapy for Hypertension

News Daily News

AHA Highlights Single-Pill Combo Therapy for Hypertension

December 17, 2025

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

News Daily News

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

December 16, 2025

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

Pediatric Hypertension On the Rise Globally

News Daily News

Pediatric Hypertension On the Rise Globally

November 28, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

October 22, 2025

ACC: It’s Time for Clinicians to Address Inflammation in CVD

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

October 03, 2025

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

News Conference News ESC 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

August 31, 2025

DAPT De-escalation Success Varies by Sex: Meta-analysis

News Daily News

DAPT De-escalation Success Varies by Sex: Meta-analysis

Yael L. Maxwell

August 21, 2025

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

July 16, 2025

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.